{"id":"W3128792891","doi":"10.1016/j.annonc.2021.01.065","title":"A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Melanoma and MAPK Pathways","field":"Biochemistry, Genetics and Molecular Biology","cited_by":88,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"Exelixis; Genentech; F. Hoffmann-La Roche","keywords":"Atezolizumab; Medicine; Triple-negative breast cancer; Internal medicine; Tolerability; Oncology; Taxane; Cohort; Breast cancer; Cancer; Adverse effect; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001489111,0.00183012,0.002360746,0.0004189173,0.0004083114,0.001238,0.000784275,0.001351232,0.00416399],"category_scores_gemma":[0.001375725,0.0007625111,0.002547836,0.0003676458,0.00110038,0.0007928518,0.0004507463,0.003212,0.0006765211],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001127774,"about_ca_system_score_gemma":0.001545593,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001707587,"about_ca_topic_score_gemma":0.005367752,"domain_scores_codex":[0.9995707,0.0002052968,0.00002112948,0.00009524697,0.0000299615,0.00007774735],"domain_scores_gemma":[0.9988853,0.0001888975,0.0002523994,0.00009233043,0.00006207106,0.0005189618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9770759,0.007801384,0.001388779,0.0003616575,0.001111347,0.00005102663,0.00004392524,0.0003116479,0.003915208,0.00006912868,0.0008942186,0.006975737],"study_design_scores_gemma":[0.9300861,0.06438506,0.003343531,0.00001832818,0.0007535342,0.00005506243,0.00001977895,0.0003163408,0.0004790031,0.00008868935,0.0004399998,0.00001450445],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9870728,0.002365631,0.0004171825,0.0006696218,0.000322386,0.005547698,0.001714709,0.00008566966,0.001804198],"genre_scores_gemma":[0.9856031,0.001925512,0.001226865,0.001089705,0.0003198755,0.004460444,0.00232698,0.00002314577,0.003024364],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00416399,"threshold_uncertainty_score":0.0139299,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03530508733216457,"score_gpt":0.3644163185437791,"score_spread":0.3291112312116145,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}